QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: GVP Module XVI Risk Minimisation Effectiveness Evaluation

Test your understanding of the concepts covered by GVP Module XVI: Risk Minimisation Effectiveness Evaluation.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why is evaluation of an additional risk-minimisation measure often concerned with incremental benefit?

Routine measures operate at the same time, so the relevant question may be whether the additional measure provides benefit beyond the existing baseline. Additional measures are evaluated independently because routine measures cease to operate once an additional measure is introduced. Incremental benefit is relevant only to commercial decision-making. Routine measures are never part of the risk-management strategy.

Question 2 of 10 A controlled-access programme records that eligibility checks were completed, but inappropriate dispensing still occurs. What does this illustrate?

A process measure can show that a required check occurred without proving that the ultimate prevention objective was achieved. Completion of a process automatically establishes clinical effectiveness. The programme has no implementation data because eligibility checks are not relevant. The only valid endpoint is the number of access-system users.

Question 3 of 10 No statistically significant reduction is observed for a rare, serious adverse outcome in a study with limited exposure. What is the most defensible conclusion?

The available evidence may be insufficient to estimate effectiveness; absence of statistical significance does not prove absence of effect. The intervention has definitively failed. The intervention has definitively prevented the outcome. The clinical outcome should be replaced by overall product sales.

Question 4 of 10 Why might a single evaluation time point be inadequate for a complex risk-minimisation programme?

Knowledge, behaviour and clinical outcomes may change on different timescales. All effectiveness endpoints must be measured only immediately after distribution. Clinical outcomes always occur before knowledge changes. A single time point automatically creates confounding.

Question 5 of 10 Why should qualitative interviews or observations sometimes be included in an effectiveness evaluation?

They can reveal workflow barriers, misunderstandings and contextual explanations that quantitative measures may not identify. They eliminate the need for behavioural or clinical outcome data. They provide statistically unbiased estimates of event incidence. They are required whenever distribution reach is high.

Question 6 of 10 Which characteristic is most important for a control group in a controlled effectiveness comparison?

It should be sufficiently comparable to the intervention population and not materially exposed to the same intervention. It should always be from a different country, regardless of healthcare-system differences. It should have a substantially higher baseline risk so that effects are easier to detect. It should receive all components of the intervention to maximize sample size.

Question 7 of 10 What is the appropriate role of the QPPV in relation to significant risk-minimisation effectiveness findings?

To ensure significant conclusions are visible within the pharmacovigilance system, appropriately escalated and acted upon, without necessarily conducting the statistical analysis personally. To personally perform every analysis and prevent delegation to specialists. To approve effectiveness claims without reviewing limitations or proposed actions. To transfer overall responsibility to an external statistical vendor.

Question 8 of 10 What should an adequate effectiveness record enable a knowledgeable reviewer to do?

Reconstruct the objective, methodology, data, analysis, limitations, interpretation and resulting risk-management decision. Confirm only that an evaluation report was commissioned. Determine the commercial return on the risk-minimisation measure. Verify that the result was statistically significant without reviewing the study design.

Question 9 of 10 Which statement best reflects the MAH's responsibility when affiliates or external vendors conduct effectiveness analyses?

The MAH retains ownership of the effectiveness process and must understand the methods, data quality, conclusions and resulting decisions. Delegating the analysis transfers the MAH's overall responsibility to the vendor. The MAH need only retain the final numerical result. Affiliate findings can be compared directly across countries without considering healthcare-system differences.

Question 10 of 10 Educational materials were sent to 98% of eligible prescribers, but only 35% opened or accessed them. What is the most appropriate interpretation?

The programme had high delivery reach but substantially lower actual exposure to the intervention. The programme was effective because delivery reach exceeded 95%. The programme failed clinically because access data are never relevant. The programme had high behavioural effectiveness because opening the material proves correct prescribing.

Knowledge Assessment: GVP Module XVI Risk Minimisation Effectiveness Evaluation

Cookie Settings